Curis (NASDAQ: CRIS) and Cellular Dynamics International (NASDAQ:ICEL) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations for Curis and Cellular Dynamics International, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Curis 0 0 3 0 3.00
Cellular Dynamics International 0 0 0 0 N/A

Curis presently has a consensus target price of $6.50, indicating a potential upside of 744.16%. Given Curis’ higher possible upside, equities research analysts clearly believe Curis is more favorable than Cellular Dynamics International.

Earnings and Valuation

This table compares Curis and Cellular Dynamics International’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Curis $7.53 million 16.77 -$60.41 million ($0.40) -1.93
Cellular Dynamics International N/A N/A N/A ($1.94) -8.53

Cellular Dynamics International has lower revenue, but higher earnings than Curis. Cellular Dynamics International is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

55.2% of Curis shares are held by institutional investors. 4.1% of Curis shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.


This table compares Curis and Cellular Dynamics International’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Curis -629.29% -250.58% -81.57%
Cellular Dynamics International -88.12% -57.59% -38.09%


Curis beats Cellular Dynamics International on 6 of the 9 factors compared between the two stocks.

About Curis

Curis, Inc. is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target programmed death ligand-1 (PDL1) and V-domain Ig suppressor of T-cell activation (VISTA) immune checkpoint proteins, both of which independently function as negative regulators of immune activation. CA-4948 is an oral small molecule drug candidate that is designed to inhibit the Interleukin-1 receptor-associated kinase 4 (IRAK4) kinase, which is a transducer of toll-like receptor or certain interleukin receptor signaling pathways.

About Cellular Dynamics International

Cellular Dynamics International, Inc. develops and produces functioning human cells in industrial quantities. The Company’s products include true human cells in multiple cell types (iCell products), human induced pluripotent stem cells (iPSCs) and custom iPSCs and iCell products (MyCell products). It markets its products for use in life science in vitro research and development, as well as applied product testing, stem cell banking and in vivo cellular therapeutics. It is also in the process of developing human cells as cellular therapeutics. The market for in vitro drug discovery, toxicity testing and applied testing, including chemical safety, has employed models, such as primary cells, transformed (immortalized) cells and live animals that act as surrogates for functioning human cells. Its iCell and MyCell products consist of iCell Cardiomyocytes, iCell Neurons, iCell DopaNeurons, iCell Endothelial Cells, iCell Hepatocytes, MyCell and Media and reprogramming kit.

Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with's FREE daily email newsletter.